Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer

被引：3
|
作者：
Piotrowska, Zofia [1 ]
Sequist, Lecia V. [1 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 03期
关键词：
ACQUIRED-RESISTANCE; INHIBITOR; HETEROGENEITY; MECHANISMS; AZD9291; MUTATIONS; THERAPY; GENE; BRAF;
D O I：
10.1016/j.jtho.2017.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：419 / 421
页数：3
相关论文
共 50 条
  • [41] EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
    Shiiya, Akihiko
    Noguchi, Takuro
    Tomaru, Utano
    Ariga, Shin
    Takashima, Yuta
    Ohhara, Yoshihito
    Taguchi, Jun
    Takeuchi, Satoshi
    Shimizu, Yasushi
    Kinoshita, Ichiro
    Koizumi, Tomonobu
    Matsuno, Yoshihiro
    Shinagawa, Naofumi
    Sakakibara-Konishi, Jun
    Dosaka-Akita, Hirotoshi
    CANCER SCIENCE, 2023, 114 (04) : 1270 - 1283
  • [42] MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer
    Nanjo, Shigeki
    Arai, Sachiko
    Wang, Wei
    Takeuchi, Shinji
    Yamada, Tadaaki
    Hata, Akito
    Katakami, Nobuyuki
    Okada, Yasunori
    Yano, Seiji
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (03) : 506 - 515
  • [43] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (41) : 71358 - 71370
  • [44] The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma
    Zhou, Wensheng
    Liu, Zhichao
    Wang, Yanan
    Zhang, Yanwei
    Qian, Fangfei
    Lu, Jun
    Wang, Huimin
    Gu, Ping
    Hu, Minjuan
    Chen, Ya
    Yang, Zhengyu
    Zhao, Ruiying
    Lou, Yuqing
    Han, Baohui
    Zhang, Wei
    CANCER MEDICINE, 2022, 11 (05): : 1299 - 1309
  • [45] Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
    Lee, Po-Hsin
    Huang, Yen-Hsiang
    Lin, Ho
    Hsu, Kuo-Hsuan
    Chen, Kun-Chieh
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    MEDICINA-LITHUANIA, 2022, 58 (07):
  • [46] Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer
    Qin, Qiong
    Li, Xiaoqing
    Liang, Xingmei
    Zeng, Lili
    Wang, Jing
    Sun, Linlin
    Zhong, Diansheng
    THORACIC CANCER, 2021, 12 (11) : 1708 - 1715
  • [47] Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
    Yochum, Zachary A.
    Cades, Jessica
    Wang, Hailun
    Chatterjee, Suman
    Simons, Brian W.
    O'Brien, James P.
    Khetarpal, Susheel K.
    Lemtiri-Chlieh, Ghali
    Myers, Kayla V.
    Huang, Eric H. -B.
    Rudin, Charles M.
    Tran, Phuoc T.
    Burns, Timothy F.
    ONCOGENE, 2019, 38 (05) : 656 - 670
  • [48] TGFβ1/integrin β3 positive feedback loop contributes to acquired EGFR TKI resistance in EGFR-mutant lung cancer
    Wang, Tao
    Zhang, Yali
    Cheng, Hanyue
    Li, Ling
    Xu, Lu
    JOURNAL OF DRUG TARGETING, 2023, 31 (03) : 269 - 277
  • [49] WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors
    Sakuma, Yuji
    Yamazaki, Yukiko
    Nakamura, Yoshiyasu
    Yoshihara, Mitsuyo
    Matsukuma, Shoichi
    Nakayama, Haruhiko
    Yokose, Tomoyuki
    Kameda, Yoichi
    Koizume, Shiro
    Miyagi, Yohei
    LABORATORY INVESTIGATION, 2012, 92 (03) : 371 - 383
  • [50] DISEASE FLARE AFTER TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH EGFR-MUTANT LUNG CANCER AND ACQUIRED RESISTANCE
    Chaft, Jamie E.
    Oxnard, Geoffrey R.
    Miller, Vincent A.
    Kris, Mark G.
    Sima, Camelia S.
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S360 - S360
12345